Stock AnalizELI LILLY & Co LLY
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
ELI LILLY & Co (LLY) is a healthcare company listed in the US with a market value of about $1.36T. In the twelve months to September 30, 2026 it had revenue of $86.5B and net income of $27.6B, a net margin of 31.9%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is future growth (5/5); the weakest is value (0/5).
Key numbers: a P/E of 46.9, a price to free cash flow of 69.1, 5-year revenue growth of 22% a year, a 5-year average ROIC of 23%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 37% below the current price.
Score: 3.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $86.5B | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B | $24.5B | $22.3B | $21.5B | $20.0B | $21.2B |
| Net income | $27.6B | $20.6B | $10.6B | $5.2B | $6.2B | $5.6B | $6.2B | $8.3B | $3.2B | -$204M | $2.7B |
| Free cash flow | $19.7B | $9.0B | $3.8B | $792M | $5.7B | $6.1B | $5.1B | $3.8B | $4.3B | $4.5B | $3.8B |
| EPS (diluted) | $30.81 | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 | $-0.19 | $2.58 |
| Net margin | 31.9% | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% |
| ROIC | — | 30.3% | 22.9% | 15.2% | 23.7% | 22.2% | 28.4% | 26.9% | 16.2% | 7.9% | 11.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 29 analysts is $1460.30, 1% above the current price; targets range from $940.00 to $1690.00; the consensus rating is “Buy”; expected EPS is $35.39 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is ELI LILLY & Co’s P/E ratio?
About 46.9, based on the last twelve months of diluted earnings per share (forward P/E about 30.4).
Is ELI LILLY & Co stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 37% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does ELI LILLY & Co pay a dividend?
Yes. The dividend yield is about 0.48%, and it has paid dividends for 10 years in our data.
Is ELI LILLY & Co a good stock to buy?
We do not give buy or sell advice. ELI LILLY & Co scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.